New Anticancer Drugs Up Costs and Life Expectancy Considerably

This article originally appeared here.
Share this content:
New Anticancer Drugs Up Costs and Life Expectancy Considerably
New Anticancer Drugs Up Costs and Life Expectancy Considerably

TUESDAY, Sept. 13, 2016 (HealthDay News) -- New anticancer drugs, which increase costs considerably, are associated with large gains in life expectancy, according to research published in the September issue of Health Affairs.

Given the high costs of new anticancer medications, David H. Howard, Ph.D., from Emory University in Atlanta, and colleagues examined whether these drugs offer value. Data from the Surveillance, Epidemiology, and End Results-Medicare database were used to assess the value of new cancer treatments in routine clinical practice for metastatic breast, lung, or kidney cancer, or chronic myeloid leukemia in 1996 to 2000 and 2007 to 2011.

The researchers observed large increases in medical costs, and these correlated with large gains in life expectancy. Lifetime costs, including costs for outpatient and inpatient care increased by $72,000 for patients with breast cancer who received physician-administered drugs; for these patients, life expectancy increased by 13 months. Patients who did not receive these drugs had much smaller changes in life expectancy and costs.

"Our results highlight the importance of considering outcomes and overall costs in routine practice when assessing the value of anticancer drugs as a group," the authors write.

Several authors disclosed being employed by Pfizer, which provided funding for the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »